



1633

Patent
Attorney's Docket No. 032775-041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

In re Patent Application of

Donald Morris, et al.

Application No.: 09/847,356

Filed: May 3, 2001

For: REOVIRUS CLEARANCE OF RAS-MEDIATED NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS

Group Art Unit: 1633

Examiner: Unassigned

4
KD
8-4-01

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ [x] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

By: 
Ping F. Hwang
Registration No. 44,164

Date: July 31, 2001



Patent
Attorney's Docket No. 032775-041

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Donald Morris, et al.)
) Group Art Unit: 1633
Application No.: 09/847,356)
) Examiner: Unassigned
Filed: May 3, 2001)
)
For: REOVIRUS CLEARANCE OF RAS-)
MEDIATED NEOPLASTIC CELLS)
FROM MIXED CELLULAR)
COMPOSITIONS)

RECEIVED
AUG 01 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

These documents are being submitted within three months of the filing date of the present application. Consequently, no fee is required pursuant to 37 C.F.R. §1.97(b).

By citing the above references, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.




Information Disclosure Statement
Attorney Docket. No. 032775-041
Application No.: 09/847,356

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____


Ping F. Hwung
Registration No. 44,164
Attorney for Applicants
Redwood Shores, CA Office
(650)-622-2300

P.O. Box 1404
Alexandria, Virginia 22313-1404

Date: July 31, 2001

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO.
032775-041APPLICATION NO.
09/847,356INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Donald Morris, et al.FILING DATE
May 3, 2001GROUP
1633 1642

JUL 3 1 2001



U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
	6,136,307		Lee, et al.	10-24-00

FOREIGN PATENT DOCUMENTS


Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	WO 99/08692		WO	02-25-1999		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
✓	Armstrong, G.D. et al., "Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes", <i>Virology</i> 138:37: 37-48 (1984).
✓	Bensinger, W.I., "Should we purge?", <i>Bone Marrow Transplant.</i> 21: 113-115 (1998).
✓	Bos, J.L., "Ras Oncogenes in Human Cancer: A Review", <i>Canc. Res.</i> 49(17): 4682-4689 (1989).
✓	Chandron and Nibert, "Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subviral particle", <i>J. of Virology</i> 72(1):467-75 (1998).
✓	Coffey, M.C., et al., "Reovirus therapy of tumors with activated Ras pathway", <i>Science</i> 282: 1332-1334 (1998).
9 ✓	Duggan, P.R., et al., "Predictive factors for long-term engraftment of autologous blood stem cells", <i>Bone Marrow Transplantation</i> 26(12): 1299-1304 (2000).
✓	Gao, J., B. Tombal and J.T. Isaacs, "Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and <i>in vitro</i> cultures from such xenografts", <i>Prostate</i> 39(1): 67-70, 1999.
✓	Gentsch, J.R.K. and Pacitti, A.F., "Effect of neuraminidase treatment of cells and effect of soluble glycoproteins of type 3 reovirus attachment to murine L cells", <i>J. Virol.</i> 56:356: 356-64 (1985).
✓	Neito, Y. and E.J. Shpall, "Autologous stem-cell transplantation for solid tumors in adults", <i>Hematol. Oncol. Clin. North Am.</i> 13(5): 939-968 (1999).
✓	Norman, K. and P. Lee, "Reovirus as a novel oncolytic agent", <i>J. Clin. Invest.</i> 105 (8): 1035-1038 (2000).
✓	Paul R.W. et al., "The alpha-anameric form of sialic acid is the minimal receptor determinant recognized by reovirus", <i>Virology</i> 172: 382-385 (1989).
9 ✓	Spyridonidis, A. et al., "Minimal residual disease in autologous hematopoietic harvests from breast cancer patients", <i>Annals of Oncology</i> 9: 821-826 (1998).
9 ✓	Stewart, D.A., et al., "Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens", <i>Bone Marrow Transplant.</i> 23(2): 111-117 (1999).
9 ✓	Strong, J.E., et al., "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus", <i>EMBO J.</i> 17: 3351-3362 (1998).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED



Substitute for form 1449A/PTD

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTORNEY'S DKT NO.
032775-041APPLICATION NO.
09/847,356APPLICANT
Donald Morris, et al.FILING DATE
May 3, 2001GROUP
1633-1642

✓	Strong, J.E. and P.W. Lee, "The v-erb V oncogene confers enhanced cellular susceptibility to reovirus infection", <i>J. Virol.</i> 70 : 612-616 (1996).		
✓	Strong, J.E., et al., "Evidence that the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency", <i>Virology</i> 197 (1): 405-411 (1993).		
9	Winter, J.N., "High-dose therapy with stem-cell transplantation in the malignant lymphomas", <i>Oncology (Huntingt)</i> 13 (12): 1635-1645 (1999).		
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.